693 related articles for article (PubMed ID: 33559069)
21. Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19.
Tokunaga Y; Sasaki T; Goto S; Adachi K; Sakoda Y; Tamada K
Mol Cancer Ther; 2022 Jan; 21(1):138-148. PubMed ID: 34675119
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
[No Abstract] [Full Text] [Related]
23. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
24. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide.
Yang P; Wang Y; Yao Z; Gao X; Liu C; Wang X; Wu H; Ding X; Hu J; Lin B; Li Q; Li M; Li X; Chen X; Qi W; Li W; Xue J; Xu H
J Am Chem Soc; 2020 Nov; 142(44):18874-18885. PubMed ID: 32966054
[TBL] [Abstract][Full Text] [Related]
25. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
26. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
27. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
28. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
29. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
[TBL] [Abstract][Full Text] [Related]
31. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
Rodriguez-Garcia A; Watanabe K; Guedan S
Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682
[TBL] [Abstract][Full Text] [Related]
33. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
34. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
35. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
[TBL] [Abstract][Full Text] [Related]
36. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
37. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
38. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
39. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
Chen W; Xian N; Lin S; Liao W; Chen M
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
[TBL] [Abstract][Full Text] [Related]
40. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
